Core Begin Period Cash Flow vs Cash And Equivalents Analysis

CLB Stock

USD 19.74 0.53 2.61%

Core Laboratories financial indicator trend analysis is way more than just evaluating Core Laboratories prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Core Laboratories is a good investment. Please check the relationship between Core Laboratories Begin Period Cash Flow and its Cash And Equivalents accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Laboratories NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Begin Period Cash Flow vs Cash And Equivalents

Begin Period Cash Flow vs Cash And Equivalents Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Core Laboratories Begin Period Cash Flow account and Cash And Equivalents. At this time, the significance of the direction appears to have no relationship.

The correlation between Core Laboratories' Begin Period Cash Flow and Cash And Equivalents is 0.02. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Cash And Equivalents in the same time period over historical financial statements of Core Laboratories NV, assuming nothing else is changed. The correlation between historical values of Core Laboratories' Begin Period Cash Flow and Cash And Equivalents is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Core Laboratories NV are associated (or correlated) with its Cash And Equivalents. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Equivalents has no effect on the direction of Begin Period Cash Flow i.e., Core Laboratories' Begin Period Cash Flow and Cash And Equivalents go up and down completely randomly.

Correlation Coefficient

0.02

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Cash And Equivalents

Most indicators from Core Laboratories' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Core Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Laboratories NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

As of December 13, 2024, Selling General Administrative is expected to decline to about 34.6 M. In addition to that, Tax Provision is expected to decline to about 4 M

	2021	2022	2023	2024 (projected)
Gross Profit	83.8M	78.9M	94.0M	171.1M
Total Revenue	470.3M	489.7M	509.8M	619.3M

Gross Profit Total Revenue

Core Laboratories fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock Total Equity	Common Stock
Total Assets		0.81	0.59	0.86	0.41	0.82	0.8	0.52	0.7	0.54	0.93	-0.15	0.54	0.73	0.54	0.85	0.68	0.75	-0.29	0.9	0.23	0.82	0.34	0.44	0.84	0.57
Short Long Term Debt Total	0.81		0.61	0.65	-0.18	0.74	1.0	0.37	0.34	0.44	0.81	-0.29	0.44	0.53	0.17	0.99	0.36	0.64	-0.45	0.98	0.06	0.58	0.44	0.51	0.52	0.51
Other Current Liab	0.59	0.61		0.81	-0.11	0.24	0.55	0.86	0.62	0.71	0.38	0.04	0.71	0.84	0.16	0.62	0.13	0.51	-0.84	0.7	-0.12	0.75	0.2	0.23	0.43	0.49
Total Current Liabilities	0.86	0.65	0.81		0.31	0.52	0.6	0.81	0.91	0.82	0.63	-0.02	0.82	0.93	0.57	0.68	0.56	0.77	-0.6	0.79	0.04	0.96	0.05	0.21	0.8	0.66
Total Stockholder Equity	0.41	-0.18	-0.11	0.31		0.31	-0.17	0.13	0.52	0.09	0.36	0.11	0.09	0.28	0.67	-0.11	0.66	0.18	0.33	-0.02	0.31	0.37	-0.1	0.03	0.57	0.1
Property Plant And Equipment Net	0.82	0.74	0.24	0.52	0.31		0.77	0.08	0.3	0.26	0.91	-0.39	0.26	0.32	0.5	0.77	0.65	0.49	0.04	0.76	0.3	0.45	0.45	0.32	0.69	0.43
Net Debt	0.8	1.0	0.55	0.6	-0.17	0.77		0.31	0.3	0.38	0.82	-0.34	0.38	0.48	0.19	0.99	0.37	0.62	-0.41	0.96	0.05	0.53	0.42	0.54	0.5	0.51
Retained Earnings	0.52	0.37	0.86	0.81	0.13	0.08	0.31		0.77	0.75	0.21	0.21	0.75	0.94	0.28	0.38	0.23	0.55	-0.84	0.5	-0.07	0.86	-0.16	0.17	0.43	0.4
Accounts Payable	0.7	0.34	0.62	0.91	0.52	0.3	0.3	0.77		0.76	0.44	0.08	0.76	0.89	0.66	0.39	0.6	0.69	-0.47	0.52	0.0	0.92	-0.13	0.07	0.75	0.58
Cash	0.54	0.44	0.71	0.82	0.09	0.26	0.38	0.75	0.76		0.26	0.1	1.0	0.81	0.56	0.44	0.44	0.48	-0.67	0.55	-0.05	0.82	-0.11	-0.11	0.67	0.56
Non Current Assets Total	0.93	0.81	0.38	0.63	0.36	0.91	0.82	0.21	0.44	0.26		-0.32	0.26	0.45	0.42	0.85	0.59	0.62	-0.04	0.85	0.23	0.55	0.5	0.53	0.71	0.51
Non Currrent Assets Other	-0.15	-0.29	0.04	-0.02	0.11	-0.39	-0.34	0.21	0.08	0.1	-0.32		0.1	0.18	-0.18	-0.33	0.14	-0.31	0.05	-0.28	0.66	0.15	-0.1	-0.42	0.13	-0.68
Cash And Short Term Investments	0.54	0.44	0.71	0.82	0.09	0.26	0.38	0.75	0.76	1.0	0.26	0.1		0.81	0.56	0.44	0.44	0.48	-0.67	0.55	-0.05	0.82	-0.11	-0.11	0.67	0.56
Net Receivables	0.73	0.53	0.84	0.93	0.28	0.32	0.48	0.94	0.89	0.81	0.45	0.18	0.81		0.47	0.55	0.48	0.67	-0.72	0.66	0.06	0.97	-0.04	0.2	0.67	0.48
Common Stock Shares Outstanding	0.54	0.17	0.16	0.57	0.67	0.5	0.19	0.28	0.66	0.56	0.42	-0.18	0.56	0.47		0.23	0.78	0.39	-0.1	0.31	-0.01	0.57	-0.26	-0.07	0.77	0.55
Non Current Liabilities Total	0.85	0.99	0.62	0.68	-0.11	0.77	0.99	0.38	0.39	0.44	0.85	-0.33	0.44	0.55	0.23		0.38	0.68	-0.44	0.99	0.03	0.6	0.46	0.53	0.56	0.57
Inventory	0.68	0.36	0.13	0.56	0.66	0.65	0.37	0.23	0.6	0.44	0.59	0.14	0.44	0.48	0.78	0.38		0.35	0.07	0.44	0.49	0.64	0.02	-0.03	0.86	0.18
Other Current Assets	0.75	0.64	0.51	0.77	0.18	0.49	0.62	0.55	0.69	0.48	0.62	-0.31	0.48	0.67	0.39	0.68	0.35		-0.43	0.74	-0.14	0.73	0.04	0.31	0.54	0.68
Other Stockholder Equity	-0.29	-0.45	-0.84	-0.6	0.33	0.04	-0.41	-0.84	-0.47	-0.67	-0.04	0.05	-0.67	-0.72	-0.1	-0.44	0.07	-0.43		-0.5	0.43	-0.6	0.17	-0.24	-0.12	-0.48
Total Liab	0.9	0.98	0.7	0.79	-0.02	0.76	0.96	0.5	0.52	0.55	0.85	-0.28	0.55	0.66	0.31	0.99	0.44	0.74	-0.5		0.03	0.71	0.4	0.49	0.64	0.62
Property Plant And Equipment Gross	0.23	0.06	-0.12	0.04	0.31	0.3	0.05	-0.07	0.0	-0.05	0.23	0.66	-0.05	0.06	-0.01	0.03	0.49	-0.14	0.43	0.03		0.16	0.29	-0.31	0.41	-0.61
Total Current Assets	0.82	0.58	0.75	0.96	0.37	0.45	0.53	0.86	0.92	0.82	0.55	0.15	0.82	0.97	0.57	0.6	0.64	0.73	-0.6	0.71	0.16		-0.02	0.15	0.79	0.5
Short Term Debt	0.34	0.44	0.2	0.05	-0.1	0.45	0.42	-0.16	-0.13	-0.11	0.5	-0.1	-0.11	-0.04	-0.26	0.46	0.02	0.04	0.17	0.4	0.29	-0.02		0.14	0.17	0.0
Intangible Assets	0.44	0.51	0.23	0.21	0.03	0.32	0.54	0.17	0.07	-0.11	0.53	-0.42	-0.11	0.2	-0.07	0.53	-0.03	0.31	-0.24	0.49	-0.31	0.15	0.14		-0.04	0.37
Common Stock Total Equity	0.84	0.52	0.43	0.8	0.57	0.69	0.5	0.43	0.75	0.67	0.71	0.13	0.67	0.67	0.77	0.56	0.86	0.54	-0.12	0.64	0.41	0.79	0.17	-0.04		0.42
Common Stock	0.57	0.51	0.49	0.66	0.1	0.43	0.51	0.4	0.58	0.56	0.51	-0.68	0.56	0.48	0.55	0.57	0.18	0.68	-0.48	0.62	-0.61	0.5	0.0	0.37	0.42

Click cells to compare fundamentals

Core Laboratories Account Relationship Matchups

Core Laboratories fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	774.7M	568.6M	580.9M	578.4M	586.4M	550.2M
Short Long Term Debt Total	381.8M	327.0M	250.3M	222.4M	215.4M	220.2M
Other Current Liab	50.8M	34.9M	28.5M	31.8M	32.4M	46.3M
Total Current Liabilities	111.6M	89.8M	90.8M	103.1M	88.1M	100.6M
Total Stockholder Equity	182.1M	75.6M	161.0M	189.0M	224.8M	131.8M
Property Plant And Equipment Net	199.2M	181.7M	172.3M	157.4M	153.5M	120.1M
Net Debt	370.7M	313.2M	232.6M	207.0M	200.3M	187.0M
Retained Earnings	160.5M	50.5M	68.3M	85.9M	120.8M	194.2M
Accounts Payable	35.6M	23.0M	29.7M	45.8M	33.5M	35.9M
Cash	11.1M	13.8M	17.7M	15.4M	15.1M	14.4M
Non Current Assets Total	553.4M	402.7M	391.8M	366.7M	363.3M	325.2M
Non Currrent Assets Other	(71.3M)	(76.9M)	(74.6M)	(73.0M)	98.6M	103.5M
Cash And Short Term Investments	11.1M	13.8M	17.7M	15.4M	15.1M	14.4M
Net Receivables	131.6M	83.2M	96.8M	106.9M	123.1M	129.1M
Common Stock Shares Outstanding	44.6M	45.0M	46.7M	46.8M	47.5M	40.8M
Liabilities And Stockholders Equity	774.7M	568.6M	580.9M	578.4M	586.4M	550.2M
Non Current Liabilities Total	480.9M	403.3M	329.1M	286.3M	268.5M	267.2M
Inventory	50.2M	38.2M	45.4M	60.4M	71.7M	39.7M
Other Current Assets	28.4M	30.7M	29.1M	28.9M	13.2M	26.0M
Other Stockholder Equity	26.8M	27.1M	97.0M	100.9M	108.6M	114.0M
Total Liab	592.5M	493.0M	419.9M	389.4M	356.6M	367.8M
Property Plant And Equipment Gross	199.2M	181.7M	172.3M	157.4M	469.3M	492.7M
Total Current Assets	221.2M	165.8M	189.1M	211.7M	223.1M	225.0M
Accumulated Other Comprehensive Income	(6.3M)	(7.2M)	(10.1M)	(3.8M)	(5.0M)	(5.2M)
Short Term Debt	11.8M	11.4M	12.3M	11.7M	10.2M	14.1M
Intangible Assets	17.5M	8.6M	8.1M	7.5M	6.9M	6.6M
Other Liab	109.9M	87.7M	91.1M	75.6M	86.9M	66.4M
Other Assets	119.4M	179.4M	107.7M	102.3M	1.0	0.95
Long Term Debt	305.3M	259.4M	188.6M	172.4M	163.1M	227.7M
Property Plant Equipment	123.5M	115.3M	172.3M	157.4M	181.0M	126.1M
Current Deferred Revenue	13.4M	5.5M	7.8M	5.9M	4.8M	4.5M
Treasury Stock	(29.4M)	(14.1M)	(4.1M)	(1.4M)	(1.6M)	(1.6M)
Net Tangible Assets	11.7M	19.6M	(58.5M)	115.6M	104.1M	109.3M
Noncontrolling Interest In Consolidated Entity	4.3M	4.1M	4.6M	4.7M	5.4M	4.6M
Retained Earnings Total Equity	160.5M	50.5M	68.3M	85.9M	77.4M	73.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Core Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Core Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Core Laboratories Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Core Laboratories Nv Stock:

How To Invest In Core

Details

Is Core Stock a good investment?

Details

What is Core Laboratories' Net Worth?

Details

Largest Oil & Gas Equipment & Services Companies

View

Largest Energy Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Laboratories NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Is Oil & Gas Equipment & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Core Laboratories. If investors know Core will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Core Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.316

Dividend Share

0.04

Earnings Share

0.53

Revenue Per Share

11.158

Quarterly Revenue Growth

0.072

The market value of Core Laboratories is measured differently than its book value, which is the value of Core that is recorded on the company's balance sheet. Investors also form their own opinion of Core Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Core Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Core Laboratories' market value can be influenced by many factors that don't directly affect Core Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Core Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Core Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Core Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Core Begin Period Cash Flow vs Cash And Equivalents Analysis

Begin Period Cash Flow vs Cash And Equivalents

Begin Period Cash Flow vs Cash And Equivalents Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Cash And Equivalents

Core Laboratories fundamental ratios Correlations

Core Laboratories Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Core Laboratories fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Debt	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Cash
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Non Current Liabilities Total	+ 0.99	Net Debt
Total Liab	+ 0.99	Non Current Liabilities Total
Total Liab	+ 0.98	Short Long Term Debt Total

Other Stockholder Equity	- 0.84	Retained Earnings
Other Stockholder Equity	- 0.84	Other Current Liab
Other Stockholder Equity	- 0.72	Net Receivables
Common Stock	- 0.68	Non Currrent Assets Other
Other Stockholder Equity	- 0.67	Cash And Short Term Investments
Other Stockholder Equity	- 0.67	Cash